Neurosciences

market opportunity

  • The size of the top-10 markets for neuromodulators is approximately $1.1 billion, growing at a rate of approximately 22 percent.(1)
  • Allergan’s market share in the top-10 neuromodulator markets is approximately 91 percent.(1)
  • The worldwide market for neuromodulators is approximately $1.4 billion, growing at a rate of approximately 21 percent.(2)
  • Allergan’s market share in the worldwide neuromodulator market is approximately 85 percent.(2)

For nearly two decades, Allergan has been committed to the research and clinical development of BOTOX® (botulinum toxin type A) to improve the physical well-being and quality of life for people around the world who suffer from a variety of serious or debilitating disorders. Today, Allergan is a world leader in neuromodulator therapy and neurosciences.

BOTOX® (Botulinum Toxin Type A)

BOTOX® has emerged as one of the world’s most versatile medicines and is approved in more than 75 countries for 20 different indications. In the United States, approved medical uses for BOTOX® include:

  • Cervical dystonia (involuntary contractions of the neck muscles causing twisting repetitive movements, or abnormal postures of the head)
  • Severe primary axillary hyperhidrosis (underarm sweating) inadequately managed with topical agents
  • Blepharospasm (uncontrollable eye blinking)
  • Strabismus (crossed eyes)
(1)  Allergan estimates of top-10 markets in constant currency for 12 months ending September 2007.
(2)  Mixture of public information (earnings releases, 10Ks, 10Qs), Allergan internal data, syndicated marketing research reports, analyst reports, Internet searches, competitive intelligence, etc. in U.S. dollars at actual exchange rates for 12 months ending September 2007.